BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

About this update from Briacell Therapeutics Corp

[{"type":"image","alt":"BriaCell Therapeutics Corp.","displaySize":"","headline":null,"caption":"BriaCell Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VF.3uZP0Y9S.3O0ulWOxbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7","width":300,"height":263}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platform","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Bria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer ","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"This study was conducted in collaboration with the NCI","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":340,"olType":false},{"type":"text","content":"PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute (NCI), the US federal government’s principal agency for cancer research and training, has been published at JCI Insight, a highly rated peer-reviewed journal dedicated to advancing biomedical research from preclinical discovery through to clinical development.","length":738,"tagName":"p"},{"type":"text","content":"Publication Title: Enhancing dendritic cell cancer vaccine by allogeneic MHC class II expression and Treg depletion (our reference 189024-INS-RG-RV-4)","length":150,"tagName":"p"},{"type":"text","content":"“These findings help us better understand the anti-tumor effects of Bria-OTS+ in cancer patients,” stated Jay A. Berzofsky, MD, PhD, Senior Investigator of NCI and coauthor of the publication. “The...

More updates from Briacell Therapeutics Corp